Galena Biopharma, Inc. (NASDAQ:SLS - Get Free Report) saw a large increase in short interest in May. As of May 31st, there was short interest totalling 12,220,000 shares, an increase of 39.5% from the May 15th total of 8,760,000 shares. Based on an average daily volume of 1,910,000 shares, the short-interest ratio is presently 6.4 days. Currently, 17.6% of the company's stock are sold short.
Insider Buying and Selling
In other Galena Biopharma news, Director Jane Wasman acquired 20,000 shares of Galena Biopharma stock in a transaction dated Friday, May 30th. The stock was purchased at an average cost of $1.69 per share, for a total transaction of $33,800.00. Following the completion of the acquisition, the director now directly owns 30,400 shares of the company's stock, valued at $51,376. This represents a 192.31% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.40% of the stock is owned by company insiders.
Institutional Investors Weigh In On Galena Biopharma
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Anson Funds Management LP grew its holdings in shares of Galena Biopharma by 535.7% in the first quarter. Anson Funds Management LP now owns 7,579,095 shares of the company's stock valued at $8,185,000 after acquiring an additional 6,386,829 shares in the last quarter. Virtu Financial LLC raised its stake in shares of Galena Biopharma by 30.9% during the 1st quarter. Virtu Financial LLC now owns 53,861 shares of the company's stock valued at $58,000 after purchasing an additional 12,706 shares during the period. Brooklyn FI LLC purchased a new stake in shares of Galena Biopharma in the fourth quarter worth about $677,000. Northern Trust Corp boosted its holdings in Galena Biopharma by 33.6% in the 4th quarter. Northern Trust Corp now owns 134,721 shares of the company's stock valued at $140,000 after purchasing an additional 33,878 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Galena Biopharma by 21.2% during the fourth quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock valued at $763,000 after buying an additional 128,355 shares during the period. 17.38% of the stock is owned by hedge funds and other institutional investors.
Galena Biopharma Trading Up 0.6%
NASDAQ SLS traded up $0.01 during trading hours on Thursday, hitting $1.57. The company's stock had a trading volume of 2,541,799 shares, compared to its average volume of 1,575,516. The company has a market capitalization of $156.65 million, a PE ratio of -4.13 and a beta of 2.25. Galena Biopharma has a 52 week low of $0.77 and a 52 week high of $2.12. The company's 50-day simple moving average is $1.56 and its two-hundred day simple moving average is $1.28.
Galena Biopharma (NASDAQ:SLS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. Research analysts anticipate that Galena Biopharma will post -0.57 EPS for the current fiscal year.
About Galena Biopharma
(
Get Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
See Also
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.